Hospital
Parkview Wabash Hospital, INC.
Parkview Wabash Hospital, INC. was paid $6.40M by Medicaid between Jan 2018 and Dec 2024, across 88 billing codes. Its largest line is 99283, emergency room visit (moderate) — 42% of everything it billed.
33Billing provider infoPARKVIEW WABASH HOSPITAL, INC.
WABASH, IN 46992
WABASH, IN 46992
33aNPI1245259878assigned 07/18/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.40M
24GClaims126,270
24DCodes billed88
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Indiana
Rank by total paid#42 of 69
Median peer was paid$9.76M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RISSER, STANTON controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12,875 | $190K | |
| 2019 | 12,472 | $344K | |
| 2020 | 10,739 | $433K | |
| 2021 | 20,202 | $1.02M | |
| 2022 | 22,539 | $1.26M | |
| 2023 | 30,342 | $1.92M | |
| 2024incomplete | 17,101 | $1.24M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 42% | 16,866 | 13,794 | $2.72M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 8,072 | 5,904 | $970K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 8.5% | 2,740 | 1,919 | $546K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 4.9% | 5,918 | 1,214 | $311K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.8% | 3,874 | 2,928 | $244K |
| 71045 | Radiologic examination, chest; single view | 3.7% | 1,854 | 1,444 | $236K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2.2% | 598 | 455 | $139K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.6% | 1,608 | 1,347 | $102K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 1,676 | 968 | $81K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.3% | 13,506 | 10,096 | $80K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 456 | 398 | $80K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 13,297 | 10,391 | $78K |
76 more codes
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | 1.1% | 863 | $72K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 420 | $67K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.0% | 175 | $66K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,296 | $60K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 653 | $56K |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,082 | $42K |
| 80076 | <1% | 6,661 | $39K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,524 | $32K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 433 | $30K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 771 | $27K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 371 | $24K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 292 | $23K |
| 83605 | <1% | 2,418 | $20K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 755 | $19K |
| 99221 | <1% | 29 | $18K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 205 | $17K |
| 81001 | <1% | 3,976 | $14K | |
| 80050 | General health panel | <1% | 99 | $13K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 392 | $12K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 103 | $11K |
| 84484 | <1% | 1,215 | $11K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,163 | $11K |
| 83690 | <1% | 2,388 | $11K | |
| 99217 | <1% | 32 | $10K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 126 | $9K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 328 | $8K |
| 80061 | Lipid panel | <1% | 1,013 | $7K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 15 | $7K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 13 | $7K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 152 | $7K |
| 80053 | Comprehensive metabolic panel | <1% | 1,076 | $6K |
| 83735 | <1% | 687 | $5K | |
| 99219 | <1% | 16 | $5K | |
| 84439 | <1% | 835 | $5K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 427 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 982 | $4K |
| 80305 | <1% | 374 | $4K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 51 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 461 | $3K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 32 | $3K |
| 85027 | <1% | 651 | $3K | |
| 99285 | Emergency room visit (most serious) | <1% | 73 | $2K |
| 82607 | <1% | 151 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 108 | $2K |
| 82746 | <1% | 103 | $2K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 33 | $1K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 29 | $1K |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 955 | $1K |
| 87634 | <1% | 20 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 27 | $1K |
| 82150 | <1% | 451 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 387 | $1K |
| 81003 | <1% | 353 | $1K | |
| 85379 | <1% | 121 | $755.35 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 46 | $737.13 |
| 87081 | <1% | 133 | $735.89 | |
| 87040 | <1% | 99 | $629.69 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 75 | $586.20 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 35 | $569.56 |
| 82962 | <1% | 105 | $532.03 | |
| 84460 | <1% | 104 | $238.99 | |
| 86592 | <1% | 42 | $155.98 | |
| 81025 | <1% | 13 | $94.71 | |
| 96376 | <1% | 77 | $85.48 | |
| 80051 | <1% | 17 | $54.61 | |
| 82565 | <1% | 17 | $39.91 | |
| 84520 | <1% | 17 | $30.76 | |
| 82553 | <1% | 14 | $19.43 | |
| 82550 | <1% | 15 | $18.64 | |
| 85730 | <1% | 20 | $14.40 | |
| 85610 | <1% | 20 | $9.40 | |
| A9270 | Non-covered item or service | 0% | 52 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 139 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 20 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 277 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 102 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRISSER, STANTON (ACFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.